CD4 and neoplasm: Consistent with previous findings, immune subset profiling of Vaccine/Bintrafusp/SX-treated tumors also revealed a significant decrease in the frequency of tumor-infiltrating CD11b+F4/80-Ly6G+Ly6Clo myeloid cells and CD11b+F4/80hi macrophages, together with a marked increase of CD4+ and CD8+ T cells (Figure S3B).